FORM PTO-1449 U.S. Department of Commerce Patent and Trademark Office P29875

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)

Application No. 10/577,343

Applicant Yasuharu NISHIMURA et al.

I A Filing Date

	,		I.A. Filing D October 28,			Group 1643				
			U.S. PATE	NT DOCUME	ENTS					-
EXAMINER INITIAL		DOCUMENT NUMBER	DATE		NAME	CLASS	SUBCLASS		FILING DATE IF APPROPRIATI	
/LB/	2006	0 2 5 1 6 6 6	11/09/06	NAKATSURA et al.						
			FOREIGN PA	TENT DOCU	MENTS					
		DOCUMENT NUMBER	DATE	COU	NTRY	CLASS	SUBC	LASS	TRANSLATION YES N	
		OTHER DOCUME	NTS (Including	Author, Title	, Date, Pertinen	Pages, Etc.)				
/LB/	1	English language abstract of EP0561183 (corresponding to JP 6-46882 A, published February 22, 1994), provided by esp@cenet.								
/LB/	2	English language abstract of WO 95/29193 (corresponding to JP 10-505481, published June 2, 1998) and provided by esp@cenet.								
/LB/	3	U.S. Patent Application 12/063,165 (NISHIMURA et al.) filed February 7, 2008, and entitled "Glypican-3 (GPC-3)-Derived Tumor Rejection Antigenic Peptides Useful for HLA-A2-Positive Patients and Pharmaceutical Comprising the Same."								
/LB/	4	U.S. Patent Application 12/155,864 (NAKATSURA et al.) filed June 11, 2008, and entitled "Cancer Antigen and Use Thereof."								
/LB/	5	U.S. Patent Application 11/577,435 (NISHIMURA et al.), filed April 18, 2007, and entitled "Novel Diagnostic Kit for Malignant Melanoma."								
XAMINER		/Lynn Bristol/		DAT	E CONSIDERE	D	04	V15/200	19	
EXAMINER: I	nitial if cita	/Lynn Bristol/ ation considered, whether or not citation with next communication to applicant.	on is in conforma					/15/200 in conform		consider